PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.66%
R&D growth while AVXL reduces spending. John Neff would investigate strategic advantage.
40.35%
G&A growth above 1.5x AVXL's 2.70%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
24.17%
Other expenses growth less than half of AVXL's 100.00%. David Dodd would verify if advantage is sustainable.
22.03%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
22.03%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
-100.00%
Interest expense reduction while AVXL shows 0.00% growth. Joel Greenblatt would examine advantage.
24.17%
D&A growth while AVXL reduces D&A. John Neff would investigate differences.
-22.02%
EBITDA decline while AVXL shows 22.08% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-22.03%
Operating income decline while AVXL shows 20.97% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-9.98%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-22.30%
Pre-tax income decline while AVXL shows 21.29% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
9.98%
Tax expense growth above 1.5x AVXL's 3.05%. Michael Burry would check for concerning trends.
-22.30%
Net income decline while AVXL shows 21.25% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-22.29%
EPS decline while AVXL shows 22.92% growth. Joel Greenblatt would examine position.
-22.29%
Diluted EPS decline while AVXL shows 22.92% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.